Result of AGM

Oxford Biomedica PLC

23 June 2023

 

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 23 June 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 23 June 2023 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com  

Copies of the document setting out the above resolutions passed at the 2023 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

On the Record Date (21 June 2023) there were 96,521,209 ordinary shares of 50 pence each in issue, each carrying one vote per share.

	Resolution	Votes For (incl. votes at the Chairman's discretion)	% of votes cast	Votes Against	% of votes cast	Votes Withheld*	Total votes cast	Result
	Ordinary resolutions
1	To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022.	73,060,750	100.00%	629	0.00%	146,857	73,061,379	PASS
2	To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2022.	51,080,127	79.93%	12,826,613	20.07%	9,301,496	63,906,740	PASS
3	To appoint Dr. Frank Mathias as a Director.	73,062,102	99.81%	137,244	0.19%	8,890	73,199,346	PASS
4	To appoint Leone Patterson as a Director.	72,892,590	99.58%	307,356	0.42%	8,290	73,199,946	PASS
5	To reappoint Dr. Roch Doliveux as a Director.	67,536,075	92.26%	5,662,468	7.74%	9,693	73,198,543	PASS
6	To reappoint Professor Dame Kay Davies as a Director.	66,057,059	90.24%	7,141,705	9.76%	9,472	73,198,764	PASS
7	To reappoint Stuart Paynter as a Director.	72,551,391	99.11%	649,338	0.89%	7,507	73,200,729	PASS
8	To reappoint Stuart Henderson as a Director.	66,051,339	90.25%	7,139,682	9.75%	17,215	73,191,021	PASS
9	To reappoint Dr. Heather Preston as a Director	64,485,621	88.10%	8,713,178	11.90%	9,437	73,198,799	PASS
10	To reappoint Robert Ghenchev as a Director.	73,059,336	99.81%	140,259	0.19%	8,641	73,199,595	PASS
11	To reappoint Dr. Michael Hayden as a Director.	67,826,937	92.66%	5,371,827	7.34%	9,472	73,198,764	PASS
12	To reappoint Catherine Moukheibir as a Director.	68,240,515	93.22%	4,959,431	6.78%	8,290	73,199,946	PASS
13	To reappoint Namrata P. Patel as a Director.	73,140,356	99.92%	59,590	0.08%	8,290	73,199,946	PASS
14	To appoint PriceWaterhouseCoopers LLP as auditor.	73,193,707	99.99%	7,290	0.01%	7,239	73,200,997	PASS
15	To authorise the Directors to agree the remuneration of the auditor.	73,195,908	99.99%	4,776	0.01%	7,552	73,200,684	PASS
16	To authorise the Directors to allot shares.	70,498,713	96.31%	2,702,643	3.69%	6,880	73,201,356	PASS
	Special resolutions
17	To authorise the Directors to disapply pre-emption rights.	72,202,544	98.64%	996,404	1.36%	9,288	73,198,948	PASS
18	To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.	70,474,362	96.28%	2,721,812	3.72%	12,062	73,196,174	PASS
19	To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.	71,049,162	97.06%	2,150,941	2.94%	8,133	73,200,103	PASS

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

In addition, further to the announcement by the Company in January, Dr. Siyamak Rasty has stepped down from the Company's Board of Directors with effect from the conclusion of today's AGM.

The Board recognises that, whilst resolution 2 was passed with a clear majority at almost 80%, there was also a significant vote against this resolution. The Board will seek to engage with those shareholders who voted against this resolution and it is anticipated that a revised remuneration policy will be presented to shareholders for their approval at the Company's AGM in 2024. In accordance with the UK Corporate Governance Code, an update on the views received from shareholders and details of any further actions taken by the Company will be published no later than 23 December 2023 by way of Stock Exchange Announcement. A summary will also be published in the 2023 Annual Report and Accounts.

-Ends-

Enquiries:        Oxford Biomedica plc: Taylor Boyd, VP, Head of IR - T: [phone]/ E: [e-mail] Sophia Bolhassan, VP, Corporate Affairs and IR - T: [phone] / E: [e-mail] Consilium Strategic Communications: T: [phone] / E: [e-mail] Mary-Jane Elliott / Matthew Neal / Davide Salvi

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

END